Equity Overview
Price & Market Data
Price: $7.01
Daily Change: -$0.11 / 1.57%
Daily Range: $6.95 - $7.19
Market Cap: $149,422,432
Daily Volume: 101,796
Performance Metrics
1 Week: -7.78%
1 Month: -1.96%
3 Months: 38.14%
6 Months: 37.87%
1 Year: -45.60%
YTD: 21.57%
Company Details
Employees: 131
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.